M&A

Vanda Pharmaceuticals to Acquire the US and Canadian Rights for Ponvory from Actelion to Treat Relapsing Multiple Sclerosis

Vanda Pharmaceuticals to Acquire the US and Canadian Rights for Ponvory from Actelion to Treat Relapsing Multiple Sclerosis

Shots: Vanda signed an agreement with Actelion (a subsidiary of Johnson & John...

AbbVie to Acquire Cerevel Therapeutics for ~$8.7B

AbbVie to Acquire Cerevel Therapeutics for ~$8.7B

Shots: Both AbbVie and Cerevel Therapeutics have signed a definitive agreement as...

Roche to Acquire  Carmot Therapeutics for ~$3.1B

Roche to Acquire Carmot Therapeutics for ~$3.1B

Shots: Roche announces the acquisition of Carmot Therapeutics providing access to...

AbbVie to Acquire ImmunoGen for $10.1B

AbbVie to Acquire ImmunoGen for $10.1B

Shots: AbbVie announces the acquisition of ImmunoGen, including its Elahere antibo...

Sosei Heptares Initiates to Reclaim Ownership GSK4381406 from GSK

Sosei Heptares Initiates to Reclaim Ownership GSK4381406 from GSK

Shots: Sosei Heptares intends to regain full ownership of GSK4381406, an oral GPR3...

Boehringer Ingelheim Acquires T3 Pharma for $508.2M

Boehringer Ingelheim Acquires T3 Pharma for $508.2M

Shots: The company announces the acquisition of T3 Pharma to expand its immuno-onc...

Image